clinical trial · NCT04520139
Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
University of California, Irvine·phase2·not yet recruiting·n = 102
Ovarian CancerCognitive ImpairmentN-Acetyl-CysteinePlacebo
brief summary
This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).
started
May 1, 2026
primary completion
Dec 1, 2026
completion
Dec 1, 2027
last updated
Apr 29, 2026
official title
Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol